16454
2016
eng
936
16
article
1
2018-07-16
--
--
Tumour stage distribution and survival of malignant melanoma in Germany 2002-2011
Background
Over the past two decades, there has been a rising trend in malignant melanoma incidence worldwide. In 2008, Germany introduced a nationwide skin cancer screening program starting at age 35. The aims of this study were to analyse the distribution of malignant melanoma tumour stages over time, as well as demographic and regional differences in stage distribution and survival of melanoma patients.
Methods
Pooled data from 61 895 malignant melanoma patients diagnosed between 2002 and 2011 and documented in 28 German population-based and hospital-based clinical cancer registries were analysed using descriptive methods, joinpoint regression, logistic regression and relative survival.
Results
The number of annually documented cases increased by 53.2% between 2002 (N = 4 779) and 2011 (N = 7 320). There was a statistically significant continuous positive trend in the proportion of stage UICC I cases diagnosed between 2002 and 2011, compared to a negative trend for stage UICC II. No trends were found for stages UICC III and IV respectively. Age (OR 0.97, 95% CI 0.97–0.97), sex (OR 1.18, 95% CI 1.11–1.25), date of diagnosis (OR 1.05, 95% CI 1.04–1.06), ‘diagnosis during screening’ (OR 3.24, 95% CI 2.50–4.19) and place of residence (OR 1.23, 95% CI 1.16–1.30) had a statistically significant influence on the tumour stage at diagnosis. The overall 5-year relative survival for invasive cases was 83.4% (95% CI 82.8–83.9%).
Conclusions
No distinct changes in the distribution of malignant melanoma tumour stages among those aged 35 and older were seen that could be directly attributed to the introduction of skin cancer screening in 2008.
"
BMC Cancer
10.1186/s12885-016-2963-0
urn:nbn:de:bvb:20-opus-164544
BMC Cancer (2016) 16:936
false
true
CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International
Olaf Schoffer
Stefanie Schülein
Gerlinde Arand
Hans Arnholdt
Dieter Baaske
Ralf C. Bargou
Nikolaus Becker
Matthias W. Beckmann
Yves Bodack
Beatrix Böhme
Tayfun Bozkurt
Regine Breitsprecher
Andre Buchali
Elke Burger
Ulrike Burger
Klaus Dommisch
Gudrun Elsner
Karin Fernschild
Ulrike Flintzer
Uwe Funke
Michael Gerken
Hubert Göbel
Norbert Grobe
Vera Gumpp
Lucie Heinzerling
Lana Raffaela Kempfer
Alexander Kiani
Monika Klinkhammer-Schalke
Sabine Klöcking
Ute Kreibich
Katrin Knabner
Peter Kuhn
Stine Lutze
Uwe Mäder
Tanja Maisel
Jan Maschke
Martin Middeke
Andreas Neubauer
Antje Niedostatek
Anabelle Opazo-Saez
Christoph Peters
Beatrice Schell
Gerhard Schenkirsch
Harald Schmalenberg
Peter Schmidt
Constanze Schneider
Birgit Schubotz
Anika Seide
Paul Strecker
Sabine Taubenheim
Matthias Wackes
Steffen Weiß
Claudia Welke
Carmen Werner
Christian Wittekind
Jörg Wulff
Heike Zettl
Stefanie J. Klug
eng
uncontrolled
Malignant melanoma
eng
uncontrolled
TNM staging
eng
uncontrolled
Survival analysis
eng
uncontrolled
Skin cancer screening
eng
uncontrolled
Stage distribution
Medizin und Gesundheit
open_access
Medizinische Klinik und Poliklinik II
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/16454/013_Schoffer_BMC-CANCER.pdf
13238
2013
eng
1411-1419
120
article
1
2016-04-18
--
--
Increases in CSF dopamine in HIV patients are due to the dopamine transporter 10/10-repeat allele which is more frequent in HIV-infected individuals
Dysfunction of dopaminergic neurotransmission has been implicated in HIV infection. We showed previously increased dopamine (DA) levels in CSF of therapy-naïve HIV patients and an inverse correlation between CSF DA and CD4 counts in the periphery, suggesting adverse effects of high levels of DA on HIV infection. In the current study including a total of 167 HIV-positive and negative donors from Germany and South Africa (SA), we investigated the mechanistic background for the increase of CSF DA in HIV individuals. Interestingly, we found that the DAT 10/10-repeat allele is present more frequently within HIV individuals than in uninfected subjects. Logistic regression analysis adjusted for gender and ethnicity showed an odds ratio for HIV infection in DAT 10/10 allele carriers of 3.93 (95 % CI 1.72–8.96; p = 0.001, Fishers exact test). 42.6 % HIV-infected patients harbored the DAT 10/10 allele compared to only 10.5 % uninfected DAT 10/10 carriers in SA (odds ratio 6.31), whereas 68.1 versus 40.9 %, respectively, in Germany (odds ratio 3.08). Subjects homozygous for the 10-repeat allele had higher amounts of CSF DA and reduced DAT mRNA expression but similar disease severity compared with those carrying other DAT genotypes. These intriguing and novel findings show the mutual interaction between DA and HIV, suggesting caution in the interpretation of CNS DA alterations in HIV infection solely as a secondary phenomenon to the virus and open the door for larger studies investigating consequences of the DAT functional polymorphism on HIV epidemiology and progression of disease.
Journal of Neural Transmission
10.1007/s00702-013-1086-x
urn:nbn:de:bvb:20-opus-132385
Journal of Neural Transmission (2013) 120:1411–1419 DOI 10.1007/s00702-013-1086-x
Anne Horn
Carsten Scheller
Stefan du Plessis
Gabriele Arendt
Thorsten Nolting
John Joska
Sieghart Sopper
Matthias Maschke
Mark Obermann
Ingo W. Husstedt
Johannes Hain
Tongai Maponga
Peter Riederer
Eleni Koutsilieri
eng
uncontrolled
HIV
eng
uncontrolled
HAND
eng
uncontrolled
dopamine
eng
uncontrolled
DAT
eng
uncontrolled
polymorphism
eng
uncontrolled
CSF
Krankheiten
open_access
Institut für Mathematik
Institut für Virologie und Immunbiologie
Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/13238/153_Horn_Journal_of_Neural_Transmission.pdf